Harry P. Erba

Harry P. Erba, MD, PhD is Professor of Medicine in the Division of Hematologic Malignancies and Cellular Therapy at Duke University School of Medicine and Director of the Leukemia Program at the Duke Cancer Institute. He is one of the most prominent AML clinical trialists in the United States, best known as a principal investigator of the VIALE-A trial (NEJM 2020) — the landmark phase III study demonstrating that azacitidine plus venetoclax (Aza-Ven) significantly improved overall survival versus azacitidine alone in previously untreated AML patients ineligible for intensive chemotherapy (OS 14.7 vs. 9.6 months; HR 0.66). VIALE-A established Aza-Ven as the new standard of care for elderly or unfit AML patients worldwide and led to FDA approval of this combination in 2020. Dr. Erba has been a leading investigator in IDH inhibitor trials, including the pivotal studies of enasidenib (AG-221) and ivosidenib (AG-120) in IDH2- and IDH1-mutated AML respectively, as well as combination strategies pairing IDH inhibitors with azacitidine. He has led the BEAT AML Master Protocol at the Leukemia & Lymphoma Society — a precision medicine platform trial that matches AML patients to treatment arms based on molecular profiling within 7 days of diagnosis. Dr. Erba has authored over 200 publications, lectures internationally, and serves on the ASH Scientific Program Committee and NCCN AML guidelines panel.